- Refractory Hepatic Hydrothorax in Chronic Hepatitis C Controlled by Direct-acting Antivirals
-
Kim MH, Kim DK, Eun HS, Rou WS, Kim SH, Lee BS
- KMID: 2471149
- Korean J Gastroenterol.
- 2020 Feb;75(2):98-102.
- doi: 10.4166/kjg.2020.75.2.98
Hepatic hydrothorax is a transudative pleural effusion that complicates advanced liver cirrhosis. Patients refractory to medical treatment plus salt restriction and diuretics are considered to have refractory hepatic hydrothorax and... -
- CITED
-
- Close
- SHARE
-
- Close
- What is the Long-term Benefit of Direct-acting Antiviral Therapy in Chronic Hepatitis C?
-
Kim JW
- KMID: 2460926
- J Korean Med Sci.
- 2019 Oct;34(41):e277.
- doi: 10.3346/jkms.2019.34.e277
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Development and surveillance of hepatocellular carcinoma in patients with sustained virologic response after antiviral therapy for chronic hepatitis C
-
Na SK, Song BC
- KMID: 2459785
- Clin Mol Hepatol.
- 2019 Sep;25(3):234-244.
- doi: 10.3350/cmh.2018.0108
Hepatitis C virus (HCV) infection is a major risk factor for liver cirrhosis and hepatocellular carcinoma (HCC), and is a leading cause of liver-related deaths worldwide. Recently available direct-acting antiviral... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparison of the Clinical Characteristics and Outcomes between Leprosy-Affected Persons in Sorokdo and the General Population Affected by Chronic Hepatitis C in Korea
-
Ahn YH, Park H, Lee MJ, Kim DH, Cho SB, Cho E, Jun CH, Choi SK
- KMID: 2458512
- Gut Liver.
- 2019 Sep;13(5):549-556.
- doi: 10.5009/gnl18432
BACKGROUND/AIMS: Patients with Hansen’s disease are the most vulnerable to hepatitis C. However, no data on the treatment efficacy of direct-acting antiviral agents (DAAs) are available in this group. Therefore,... -
- CITED
-
- Close
- SHARE
-
- Close
- Platelet count is associated with sustained virological response rates in treatments for chronic hepatitis C
-
Jun BG, Park EJ, Lee WC, Jang JY, Jeong SW, Kim YD, Cheon GJ, Cho YS, Lee SH, Kim HS, Lee YN, Kim SG, Kim YS, Kim BS
- KMID: 2457022
- Korean J Intern Med.
- 2019 Sep;34(5):989-997.
- doi: 10.3904/kjim.2017.322
BACKGROUND/AIMS: This study was conducted to clarify the sustained virological response (SVR) prediction ability of baseline and treatment-related factors in patients with chronic hepatitis C virus (HCV) infection. METHODS: This retrospective... -
- CITED
-
- Close
- SHARE
-
- Close
- Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world
-
Oh JY, Kim BS, Lee CH, Song JE, Lee HJ, Park JG, Hwang JS, Chung WJ, Jang BK, Kweon YO, Tak WY, Park SY, Jang SY, Suh JI, Kwak SG
- KMID: 2457309
- Korean J Intern Med.
- 2019 Jul;34(4):794-801.
- doi: 10.3904/kjim.2017.368
BACKGROUND/AIMS: Previous studies have reported a high rate of sustained virologic response (SVR) and a low rate of serious adverse events with the use of daclatasvir (DCV) and asunaprevir (ASV)... -
- CITED
-
- Close
- SHARE
-
- Close
- The Efficacy and Safety of Direct-acting Antiviral Treatment for Chronic Hepatitis C Patients: A Single Center Study
-
Park SJ, Kim AR, Choe WH, Kim JH, Yoo BC, Kwon SY
- KMID: 2424111
- Korean J Gastroenterol.
- 2018 Oct;72(4):197-204.
- doi: 10.4166/kjg.2018.72.4.197
BACKGROUND/AIMS: Direct-acting antiviral (DAA) therapy has been shown to achieve a high rate of sustained virologic response (SVR) and favorable outcomes in chronic hepatitis C (CHC) patients. We investigated the... -
- CITED
-
- Close
- SHARE
-
- Close
- Does the old-fashioned sofosbuvir plus ribavirin treatment in genotype 2 chronic hepatitis C patients still works for Koreans?
-
Yeon JE
- KMID: 2428755
- Clin Mol Hepatol.
- 2018 Sep;24(3):294-296.
- doi: 10.3350/cmh.2018.1009
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Recent update of the 2017 Korean Association for the Study of the Liver (KASL) treatment guidelines of chronic hepatitis C: Comparison of guidelines from other continents, 2017 AASLD/IDSA and 2016 EASL
-
Yeon JE
- KMID: 2428754
- Clin Mol Hepatol.
- 2018 Sep;24(3):278-293.
- doi: 10.3350/cmh.2018.1002
The paradigm for the treatment of chronic hepatitis C (CHC) has been changed due to the development of direct acting antivirals (DAAs) of hepatitis C virus (HCV). The high sustained... -
- CITED
-
- Close
- SHARE
-
- Close
- 2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C
-
The Korean Association for the Study of the Liver (KASL)
- KMID: 2428752
- Clin Mol Hepatol.
- 2018 Sep;24(3):169-229.
- doi: 10.3350/cmh.2018.1004
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Factors Associated with Health-Related Quality of Life in Korean Patients with Chronic Hepatitis C Infection Using the SF-36 and EQ-5D
-
Jang ES, Kim YS, Kim KA, Lee YJ, Chung WJ, Kim IH, Lee BS, Jeong SH
- KMID: 2417311
- Gut Liver.
- 2018 Jul;12(4):440-448.
- doi: 10.5009/gnl17322
BACKGROUND/AIMS: This study aimed to describe the health-related quality of life (HRQoL) outcomes for Korean chronic hepatitis C patients and to investigate the impact of patient and virus-related factors on... -
- CITED
-
- Close
- SHARE
-
- Close
- Chronic Hepatitis C Virus Infection, Why Not Treat Now?
-
Park KS
- KMID: 2415602
- J Rheum Dis.
- 2018 Jul;25(3):151-152.
- doi: 10.4078/jrd.2018.25.3.151
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- 2017 Korean Association for the Study of the Liver (KASL) Clinical Practice Guidelines of Chronic Hepatitis C: What's New?
-
Kim KA
- KMID: 2414456
- Korean J Gastroenterol.
- 2018 Jun;71(6):315-318.
- doi: 10.4166/kjg.2018.71.6.315
With the advent of highly effective direct-acting antiviral agents (DAA), the treatment of hepatitis C virus infections continues to change. The Korean Association for the Study of the Liver updated... -
- CITED
-
- Close
- SHARE
-
- Close
- PD-L1 Expression on Circulating CD34+ Hematopoietic Stem Cells Closely Correlated with T-cell Apoptosis in Chronic Hepatitis C Infected Patients
-
Abdellatif H, Shiha G
- KMID: 2413503
- Int J Stem Cells.
- 2018 Jun;11(1):78-86.
- doi: 10.15283/ijsc17047
BACKGROUND AND OBJECTIVES: Lack of understanding of the interplay between hematopoietic stem cells (HSCs) and the immune system has severely hampered stem cell research. Programmed death-1 (PD-L1) has been reported... -
- CITED
-
- Close
- SHARE
-
- Close
- Transaminase Changes in Korean Rheumatoid Arthritis Patients with Chronic Hepatitis C after Biologic Therapy
-
Kwon HM, Shin K, Moon JY, Lee SS, Chung WT, Lee J, Lee SH, Kang SW, Suh CH, Hong SJ, Song R, Choe JY, Song YW
- KMID: 2408928
- J Rheum Dis.
- 2018 Apr;25(2):108-115.
- doi: 10.4078/jrd.2018.25.2.108
OBJECTIVE: Coexisting chronic hepatitis C can be problematic when treating rheumatoid arthritis (RA). This study examined the changes in the transaminase and viral load in hepatitis C virus (HCV)-infected RA... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and safety of sofosbuvir-based regimens for treatment in chronic hepatitis C genotype 1 patients with moderately impaired renal function
-
Shin HP, Park JA, Burman B, Kozarek RA, Siddique A
- KMID: 2406040
- Clin Mol Hepatol.
- 2017 Dec;23(4):316-322.
- doi: 10.3350/cmh.2016.0087
BACKGROUND/AIMS: Treatment of chronic hepatitis C virus (HCV) infection in patients with chronic kidney disease (CKD) is essential. The availability of sofosbuvir (SOF) has dramatically improved overall HCV cure rates,... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical implication of serum uric acid level in pegylated interferon and ribavirin combination therapy for chronic hepatitis C infection
-
Oh IS, Won JW, Kim HJ, Lee HW
- KMID: 2396760
- Korean J Intern Med.
- 2017 Nov;32(6):1010-1017.
- doi: 10.3904/kjim.2016.405
BACKGROUND/AIMS: Combined treatment of pegylated interferon-α (PEG-IFN) and ribavirin (RBV) has long been accepted as the standard treatment for chronic hepatitis C virus (HCV) infection. Many predictive factors for treatment... -
- CITED
-
- Close
- SHARE
-
- Close
- Healthcare Costs for Chronic Hepatitis C in South Korea from 2009 to 2013: An Analysis of the National Health Insurance Claims' Data
-
Ki M, Choi HY, Kim KA, Jang ES, Jeong SH
- KMID: 2395389
- Gut Liver.
- 2017 Nov;11(6):835-842.
- doi: 10.5009/gnl17034
BACKGROUND/AIMS: The introduction of direct-acting antivirals (DAA) in 2013 revolutionized hepatitis C virus (HCV) treatment, offering a cure rate >90%. However, this therapy is expensive, and estimations of the number... -
- CITED
-
- Close
- SHARE
-
- Close
- Estimation of Direct Medical Costs Related to Chronic Hepatitis C: A Rationale for Early Antiviral Therapy
-
Kim DY
- KMID: 2395378
- Gut Liver.
- 2017 Nov;11(6):745-746.
- doi: 10.5009/gnl17408
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Direct Acting Antiviral Agents in Korean Patients with Chronic Hepatitis C and Hemophilia Who Are Treatment-Naïve or Treatment-Experienced
-
Lee HW, Yoo KY, Won JW, Kim HJ
- KMID: 2389361
- Gut Liver.
- 2017 Sep;11(5):721-727.
- doi: 10.5009/gnl17209
BACKGROUND/AIMS: Chronic hepatitis C (CHC) is a major comorbidity in patients with hemophilia. METHODS: Patients (n=30) were enrolled between September 2015 and April 2016. Twenty-six patients were genotype 1 (1b, n=21;... -
- CITED
-
- Close
- SHARE
-
- Close
